Home / Deep Research / Familial Mediterranean Fever

Familial Mediterranean Fever

Disease Pathophysiology Research Report

2025-12-15
Falcon MONDO:0018088 Model: Edison Scientific Literature 26 citations

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Familial Mediterranean Fever (FMF)
  • MONDO ID: [not specified]
  • Category: Genetic (monogenic autoinflammatory disease)

Pathophysiology overview

Familial Mediterranean fever is a prototypic inflammasomopathy caused by gain‑of‑function variants in MEFV encoding pyrin, a cytosolic inflammasome sensor in monocytes and neutrophils. Pathogenesis centers on dysregulated pyrin inflammasome assembly with downstream caspase‑1 activation, maturation and release of IL‑1β and IL‑18, gasdermin D–mediated pore formation and pyroptosis, and amplification by neutrophil/monocyte alarmins (S100 proteins). At baseline, pyrin is restrained by RhoA–PKN1/2–14‑3‑3 phosphorylation‑dependent autoinhibition; genetic variants and specific triggers lower the activation threshold and favor spontaneous or easily triggered inflammasome assembly (park2016pyrininflammasomeactivation pages 1-10, bella2024thepyrininflammasome pages 8-10, bella2024thepyrininflammasome pages 6-7, bella2024thepyrininflammasome pages 1-2).

Direct quote supporting the core mechanism: “RhoA activated the serine-threonine kinases PKN1 and PKN2 that bind and phosphorylate pyrin. Phosphorylated pyrin bound to 14-3-3 proteins… [and] blocked the pyrin inflammasome.” (Nature Immunology, 2016; URL: https://doi.org/10.1038/ni.3457; published Jun 2016) (park2016pyrininflammasomeactivation pages 1-10).

Recent reviews and experimental work in 2023–2024 refine these mechanisms by implicating PP2A activity in positively regulating pyrin via dephosphorylation, highlighting cytoskeletal control and gasdermin D as essential executioners, and identifying endogenous steroid catabolites and alarmins (S100A8/A9/A12) as important amplifiers and biomarkers in pyrin‑mediated inflammation (Frontiers in Immunology 2024, https://doi.org/10.3389/fimmu.2023.1341680; mBio 2023, https://doi.org/10.1128/mbio.02066-23; Frontiers in Pediatrics 2024, https://doi.org/10.3389/fped.2024.1421353) (bella2024thepyrininflammasome pages 8-10, bella2024thepyrininflammasome pages 6-7, bella2024thepyrininflammasome pages 5-6, chaaban2024anarrativereview pages 19-20, bella2024thepyrininflammasome pages 1-2).

Table (click to expand)
Entity Type / Ontology Identifier Role in FMF pathophysiology (one sentence) Evidence (year & DOI URL) (context ID) Notes
MEFV / pyrin Gene / inflammasome sensor (HGNC:MEFV) HGNC:MEFV Cytosolic inflammasome sensor whose gain-of-function variants lower activation threshold and drive caspase-1–dependent IL-1β/IL-18 release. 2016 10.1038/ni.3457; 2024 10.3389/fimmu.2023.1341680 (park2016pyrininflammasomeactivation pages 1-10, bella2024thepyrininflammasome pages 5-6) Central causal gene in FMF; exon 10 (B30.2) variants frequent.
PKN1 Ser/Thr kinase (GO:protein kinase activity) PKN1 Phosphorylates pyrin (S208/S242) downstream of RhoA to enforce pyrin autoinhibition. 2016 10.1038/ni.3457 (park2016pyrininflammasomeactivation pages 1-10) Works with PKN2 to enable 14-3-3 binding.
PKN2 Ser/Thr kinase (GO:protein kinase activity) PKN2 Partner kinase to PKN1 that phosphorylates pyrin and maintains 14-3-3–mediated inhibition. 2016 10.1038/ni.3457 (park2016pyrininflammasomeactivation pages 1-10) Reductions in PKN2 binding seen with pathogenic MEFV variants.
14-3-3 (YWHA family) Chaperone family (YWHA genes) YWHA* Binds phosphorylated pyrin to prevent inflammasome assembly. 2016 10.1038/ni.3457 (park2016pyrininflammasomeactivation pages 1-10) Loss of 14-3-3 binding occurs with reduced pyrin phosphorylation.
PP2A (PPP2CA/PPP2CB) Ser/Thr phosphatase (PPP family) PPP2CA / PPP2CB Phosphatase activity implicated in dephosphorylating pyrin to permit inflammasome activation. 2023 10.1128/mbio.02066-23; 2024 10.3389/fimmu.2023.1341680 (bella2024thepyrininflammasome pages 8-10, bella2024thepyrininflammasome pages 5-6) PP2A involvement described as counterbalancing PKN-mediated phosphorylation.
RhoA Small GTPase (HGNC:RHOA) RHOA Upstream GTPase whose inactivation (by toxins or prenylation defects) reduces PKN activity and relieves pyrin inhibition. 2016 10.1038/ni.3457; 2024 10.3389/fimmu.2023.1341680 (park2016pyrininflammasomeactivation pages 1-10, bella2024thepyrininflammasome pages 5-6) Targets of bacterial effectors converge here.
ASC (PYCARD) Inflammasome adaptor (HGNC:PYCARD) PYCARD Adaptor recruited by pyrin PYD to assemble ASC specks and recruit pro–caspase-1. 2024 10.3389/fimmu.2023.1341680 (bella2024thepyrininflammasome pages 5-6) Required for caspase-1 activation and downstream signaling.
CASP1 (caspase-1) Effector protease (CASP family) CASP1 Cleaves pro–IL-1β and pro–IL-18 to active forms and cleaves GSDMD to trigger pyroptosis. 2016 10.1038/ni.3457; 2024 10.3389/fimmu.2023.1341680 (park2016pyrininflammasomeactivation pages 1-10, bella2024thepyrininflammasome pages 5-6) Central executor of canonical inflammasome responses.
GSDMD (gasdermin D) Pore-forming effector (GSDM family) GSDMD N-terminal fragment forms membrane pores enabling cytokine release and pyroptotic cell death. 2024 10.3389/fimmu.2023.1341680; 2024 10.3389/fped.2024.1421353 (bella2024thepyrininflammasome pages 8-10, chaaban2024anarrativereview pages 19-20) GSDMD pores also permit release of alarmins (S100 proteins).
IL1B (IL‑1β) Proinflammatory cytokine (HGNC:IL1B) IL1B Principal downstream cytokine driving fever, serositis and systemic inflammation in FMF. 2016 10.1038/ni.3457; 2024 10.3389/fped.2024.1421353 (park2016pyrininflammasomeactivation pages 1-10, chaaban2024anarrativereview pages 19-20) Target of effective biologic therapies in colchicine-resistant disease.
IL18 Proinflammatory cytokine (HGNC:IL18) IL18 Co-released with IL-1β from pyrin inflammasome activation and contributes to inflammation. 2016 10.1038/ni.3457; 2024 10.3389/fped.2024.1421353 (park2016pyrininflammasomeactivation pages 1-10, chaaban2024anarrativereview pages 19-20) Elevated in FMF flares and some steady‑state measurements.
S100A8/A9/A12 (alarmins) Damage-associated proteins (CHEBI/S100 family) S100A8 / S100A9 / S100A12 Neutrophil/monocyte alarmins released during pyroptosis that amplify inflammation and serve as biomarkers. 2024 10.3389/fimmu.2023.1341680; 2024 10.3389/fped.2024.1421353 (bella2024thepyrininflammasome pages 8-10, chaaban2024anarrativereview pages 19-20) S100A levels correlate with disease activity and may be GSDMD-dependent.
PSTPIP1 (CD2BP1) Cytoskeletal adaptor (HGNC:PSTPIP1) PSTPIP1 Interacts with pyrin to modulate oligomerization and inflammasome assembly; variants linked to hyperinflammation. 2024 10.3389/fimmu.2023.1341680 (bella2024thepyrininflammasome pages 5-6) Mutations can produce overlapping autoinflammatory phenotypes.
Colchicine Drug / microtubule inhibitor (CHEBI) CHEBI:Colchicine First‑line therapy that disrupts microtubules and reduces pyrin inflammasome activation and attacks. 2024 10.15167/bustaffa-marta_phd2024-05-28; 2024 10.3389/fimmu.2023.1341680 (bustaffa2024theeurofeverfmf pages 76-79, bella2024thepyrininflammasome pages 5-6) Effective for attack prevention and amyloidosis prophylaxis; some genotypes show reduced response.
Anakinra IL‑1 receptor antagonist (drug) ANAKINRA Blocks IL‑1 signaling to rapidly control pyrin-mediated systemic inflammation in colchicine‑resistant cases. 2024 10.3389/fped.2024.1421353; 2024 10.15167/bustaffa-marta_phd2024-05-28 (chaaban2024anarrativereview pages 19-20, bustaffa2024theeurofeverfmf pages 76-79) Used off‑label/approved in refractory FMF; rapid onset.
Canakinumab Anti–IL‑1β monoclonal antibody (drug) CANAKINUMAB Neutralizes IL‑1β to reduce flares in patients unresponsive or intolerant to colchicine. 2024 10.3389/fped.2024.1421353; 2024 10.15167/bustaffa-marta_phd2024-05-28 (chaaban2024anarrativereview pages 19-20, bustaffa2024theeurofeverfmf pages 76-79) Long‑acting IL‑1β blockade option.
Rilonacept IL‑1 trap (biologic) RILONACEPT Binds IL‑1α/β preventing receptor engagement and decreasing FMF inflammation in resistant cases. 2024 10.3389/fped.2024.1421353 (chaaban2024anarrativereview pages 19-20) Alternative IL‑1–directed therapy.
GGPP (geranylgeranyl pyrophosphate) Metabolite (CHEBI) GGPP Prenylation substrate whose deficiency (e.g., in HIDS) leads to RhoA inactivation and pyrin activation; exogenous GGPP can suppress response. 2016 10.1038/ni.3457 (park2016pyrininflammasomeactivation pages 1-10) Links metabolic/prenylation defects to pyrin activation.
Pregnanolone & etiocholanolone Steroid catabolites (CHEBI) Pregnanolone / Etiocholanolone Endogenous catabolites that can directly activate pyrin (B30.2-dependent) independent of RhoA. 2024 10.3389/fimmu.2023.1341680 (bella2024thepyrininflammasome pages 6-7) May explain non‑infectious triggers of flares.
Yersinia effectors (YopE/YopT/YopM) Bacterial virulence proteins YopE / YopT / YopM Pathogen effectors that inactivate RhoA (YopE/T) or modulate PKN/14‑3‑3 (YopM) to trigger or evade pyrin responses. 2016 10.1038/ni.3457; 2020 10.1038/s41590-020-0705-6 (park2016pyrininflammasomeactivation pages 1-10) Historical selection of MEFV variants linked to resistance to Y. pestis (see Park et al.).
C. difficile TcdB Bacterial toxin TcdB Toxin that inactivates Rho GTPases and can trigger pyrin inflammasome activation. 2024 10.3389/fimmu.2023.1341680 (bella2024thepyrininflammasome pages 6-7) Example of non‑Yersinia effector causing RhoA perturbation.
Neutrophils Immune cell (CL:0000775) CL:0000775 Major effector cells in FMF attacks that release IL‑1, S100 alarmins, form NETs and undergo pyroptosis contributing to tissue inflammation. 2024 10.3389/fimmu.2023.1341680; 2024 10.3389/fped.2024.1421353 (bella2024thepyrininflammasome pages 8-10, chaaban2024anarrativereview pages 19-20) Abundant in serosal and synovial inflammatory infiltrates during attacks.
Monocytes / macrophages Immune cell (CL:0000235) CL:0000235 Primary cells where pyrin inflammasome assembles, producing IL‑1β/IL‑18 and driving systemic symptoms. 2016 10.1038/ni.3457; 2024 10.3389/fimmu.2023.1341680 (park2016pyrininflammasomeactivation pages 1-10, bella2024thepyrininflammasome pages 5-6) Source of circulating IL‑1 and priming signals.
Peritoneum Tissue (UBERON) UBERON:0002106 Frequent anatomical site of FMF serositis causing abdominal pain during attacks. 2024 10.15167/bustaffa-marta_phd2024-05-28 (bustaffa2024theeurofeverfmf pages 76-79) Clinically implicated in peritonitis episodes.
Pleura Tissue (UBERON) UBERON:0001004 Site of pleuritic pain/serositis in FMF attacks. 2024 10.15167/bustaffa-marta_phd2024-05-28 (bustaffa2024theeurofeverfmf pages 76-79) Pleuritis is a common attack manifestation.
Synovium Tissue (UBERON) UBERON:0002381 Joint tissue involved in FMF arthritis during inflammatory episodes. 2024 10.15167/bustaffa-marta_phd2024-05-28 (bustaffa2024theeurofeverfmf pages 76-79) Acute mono/oligoarthritis is typical.
Kidney (AA amyloidosis) Organ / pathology (UBERON / HP) UBERON:0002113 / HP:0001973 Major long-term complication from chronic IL‑1–driven inflammation leading to AA amyloid deposition and renal impairment. 2024 10.15167/bustaffa-marta_phd2024-05-28; 2024 10.3389/fimmu.2023.1341680 (bustaffa2024theeurofeverfmf pages 76-79, bella2024thepyrininflammasome pages 5-6) Risk reduced by effective colchicine and IL‑1 suppression.

Table: Compact ontology‑grounded table summarizing key genes, proteins, cells, tissues, triggers and therapies in FMF with evidence links to the gathered literature (pqac context IDs and DOIs).

1. Core pathophysiology

2. Key molecular players

3. Biological processes (GO) disrupted

4. Cellular components (GO)

5. Disease progression: triggers to manifestations

Evolutionary context: MEFV variants show signals of positive selection in Mediterranean populations, with functional data linking mutant pyrin to resistance against Yersinia pestis via preserved IL‑1β responses despite YopM-mediated suppression (Nature Immunology 2020, https://doi.org/10.1038/s41590-020-0705-6; published Jun 2020) (park2016pyrininflammasomeactivation pages 1-10).

6. Phenotypic manifestations and mechanisms (HP terms)

7. Recent developments (2023–2024), applications, expert opinions

Expert synthesis from a 2024 pediatric rheumatology perspective: pyrin inflammasome activation is “strictly dependent on homeostasis‑altering molecular processes,” with RhoA–PKN–14‑3‑3 regulation, cytoskeletal cues, GSDMD pores, and S100 alarmins forming an integrated axis of dysregulated innate immunity in FMF (Frontiers in Immunology 2024, published Jan 2024; URL: https://doi.org/10.3389/fimmu.2023.1341680) (bella2024thepyrininflammasome pages 1-2).

8. Gene/protein annotations with ontology and processes

9. Phenotype associations (HP), cells (CL), anatomy (UBERON), chemicals (CHEBI)

10. Current applications and real-world implementations

11. Relevant statistics and data

  • Real‑world cohort synthesis (Eurofever FMF longitudinal update, 2024) underscores widespread colchicine use as first‑line with escalation to IL‑1 inhibitors in nonresponders and confirms serosal/arthritis predominance; genotype–phenotype observations include higher risk of severe disease (e.g., amyloidosis) in certain MEFV genotypes (URL: https://doi.org/10.15167/bustaffa-marta_phd2024-05-28; May 2024). Specific numerical rates were not extractable from the gathered excerpt, but the report documents these patterns across multinational centers (bustaffa2024theeurofeverfmf pages 76-79).
  • Cytokine profiling in clinical and ex vivo studies demonstrates elevated IL‑1β and IL‑18 during flares with broader proinflammatory cytokines (IL‑6, TNF‑α), consistent with pyrin‑caspase‑1 activation (Frontiers in Pediatrics 2024, https://doi.org/10.3389/fped.2024.1421353; Jul 2024) (chaaban2024anarrativereview pages 3-4).

12. Evidence items (with URLs and dates)

Conclusion

FMF pathophysiology is driven by a failure of the RhoA–PKN1/2–14‑3‑3 checkpoint that restrains pyrin, with MEFV variants and specific triggers enabling PP2A‑assisted dephosphorylation and assembly of the pyrin inflammasome. Caspase‑1–dependent IL‑1β/IL‑18 release and GSDMD‑mediated pyroptosis, together with S100 alarmin amplification, explain the febrile serositis, arthritis, and risk of AA amyloidosis. 2023–2024 work highlights PP2A as a positive regulator and integrates cytoskeletal control, endogenous steroid catabolites, and alarmin biology into an updated model. Clinically, colchicine remains foundational, while IL‑1–targeted biologics are effective for colchicine‑resistant disease (park2016pyrininflammasomeactivation pages 1-10, bella2024thepyrininflammasome pages 8-10, bella2024thepyrininflammasome pages 6-7, bella2024thepyrininflammasome pages 5-6, chaaban2024anarrativereview pages 19-20, chaaban2024anarrativereview pages 3-4, bustaffa2024theeurofeverfmf pages 76-79, bella2024thepyrininflammasome pages 1-2).

References

  1. (park2016pyrininflammasomeactivation pages 1-10): Yong Hwan Park, Geryl Wood, Daniel L Kastner, and Jae Jin Chae. Pyrin inflammasome activation and rhoa signaling in the autoinflammatory diseases fmf and hids. Nature Immunology, 17:914-921, Jun 2016. URL: https://doi.org/10.1038/ni.3457, doi:10.1038/ni.3457. This article has 646 citations and is from a highest quality peer-reviewed journal.

  2. (bella2024thepyrininflammasome pages 8-10): Saverio La Bella, Armando Di Ludovico, Giulia Di Donato, Ozge Basaran, Seza Ozen, Marco Gattorno, Francesco Chiarelli, and Luciana Breda. The pyrin inflammasome, a leading actor in pediatric autoinflammatory diseases. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2023.1341680, doi:10.3389/fimmu.2023.1341680. This article has 23 citations and is from a peer-reviewed journal.

  3. (bella2024thepyrininflammasome pages 6-7): Saverio La Bella, Armando Di Ludovico, Giulia Di Donato, Ozge Basaran, Seza Ozen, Marco Gattorno, Francesco Chiarelli, and Luciana Breda. The pyrin inflammasome, a leading actor in pediatric autoinflammatory diseases. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2023.1341680, doi:10.3389/fimmu.2023.1341680. This article has 23 citations and is from a peer-reviewed journal.

  4. (bella2024thepyrininflammasome pages 1-2): Saverio La Bella, Armando Di Ludovico, Giulia Di Donato, Ozge Basaran, Seza Ozen, Marco Gattorno, Francesco Chiarelli, and Luciana Breda. The pyrin inflammasome, a leading actor in pediatric autoinflammatory diseases. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2023.1341680, doi:10.3389/fimmu.2023.1341680. This article has 23 citations and is from a peer-reviewed journal.

  5. (bella2024thepyrininflammasome pages 5-6): Saverio La Bella, Armando Di Ludovico, Giulia Di Donato, Ozge Basaran, Seza Ozen, Marco Gattorno, Francesco Chiarelli, and Luciana Breda. The pyrin inflammasome, a leading actor in pediatric autoinflammatory diseases. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2023.1341680, doi:10.3389/fimmu.2023.1341680. This article has 23 citations and is from a peer-reviewed journal.

  6. (chaaban2024anarrativereview pages 19-20): Ahlam Chaaban, Hasan Yassine, Razane Hammoud, Ruba Kanaan, Louna Karam, and José-Noel Ibrahim. A narrative review on the role of cytokines in the pathogenesis and treatment of familial mediterranean fever: an emphasis on pediatric cases. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1421353, doi:10.3389/fped.2024.1421353. This article has 10 citations and is from a poor quality or predatory journal.

  7. (bustaffa2024theeurofeverfmf pages 76-79): MARTA BUSTAFFA. The eurofever fmf longitudinal cohort: first update on the longitudinal data. Other, May 2024. URL: https://doi.org/10.15167/bustaffa-marta_phd2024-05-28, doi:10.15167/bustaffa-marta_phd2024-05-28. This article has 0 citations.

  8. (chaaban2024anarrativereview pages 3-4): Ahlam Chaaban, Hasan Yassine, Razane Hammoud, Ruba Kanaan, Louna Karam, and José-Noel Ibrahim. A narrative review on the role of cytokines in the pathogenesis and treatment of familial mediterranean fever: an emphasis on pediatric cases. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1421353, doi:10.3389/fped.2024.1421353. This article has 10 citations and is from a poor quality or predatory journal.